← All trials
NCT05692570
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 9, 2022
- Primary completion
- Nov 12, 2022
- Completion date
- Nov 12, 2022
- First posted
- Jan 20, 2023
- Last posted
- Jan 20, 2023
- Enrollment
- 21
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pyramid BiosciencesLead sponsor
- Pyramid BiosciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.